UK’s BGMA Condemns Anti-Competitive Behavior
Executive Summary
The BGMA has condemned anti-competitive behavior in the UK after Aspen paid the NHS £8m in a landmark case over “illegal market sharing”.
You may also be interested in...
UK’s CMA Issues Fines Over Fludrocortisone
The UK’s Competition and Markets Authority has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
UK’s CMA Issues Fines Over Fludrocortisone
The UK’s CMA has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
UK’s CMA Reveals Details Of Fludrocortisone Probe
The UK’s CMA has accused Tiofarma and Amilco of colluding with Aspen over an illegal agreement that resulted in significant price hikes for fludrocortisone.